The basis for treatment in multiple sclerosis.
Contemporary licensed treatments for multiple sclerosis fail to provide a solution for the disease because their effects are limited to a modest reduction in the frequency of new episodes. They do not reduce disability or materially influence the progressive phase of the disease. A contemporary strategy for management requires a more detailed analysis of the separate contributions to the clinical features and overall course made by inflammation, axonal injury, compensatory mechanisms, and remyelination. From this formulation emerges the need either for early and fully effective suppression of the inflammatory response, limiting the damage to all components of the axon-glial unit; or the development of strategies for axonal and myelin repair that solve the issues of controlled differentiation, delivery and timing of these cell and growth factor-based interventions.
Compston
A
A
Department of Clinical Neurosciences, University of Cambridge Clinical School, Cambridge, UK. alastair.compston@medschl.cam.ac.uk
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001369:Axons / Q000473:pathology; D006801:Humans; D018836:Inflammation Mediators / Q000502:physiology; D009103:Multiple Sclerosis / Q000473:pathology / Q000503:physiopathology* / Q000628:therapy*; D009186:Myelin Sheath / Q000502:physiology; D009414:Nerve Growth Factors / Q000502:physiology; D020127:Recovery of Function / Q000502:physiology
D000276:Adjuvants, Immunologic; D000893:Anti-Inflammatory Agents; D018836:Inflammation Mediators; D009414:Nerve Growth Factors